Extent of fungal contamination in rat-derived Pneumocystis carinii extracts and the effect on uptake of para-aminobenzoic acid.
Chung
V
V
Dept. Chemotherapy, Glaxo Research and Development Limited, Greenford, Middlesex, UK.
Shah
K
K
D010129:4-Aminobenzoic Acid / Q000493:pharmacokinetics*; D000818:Animals; D000935:Antifungal Agents / Q000494:pharmacology; D001693:Biological Transport, Active / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects / Q000302:isolation & purification / Q000378:metabolism; D005658:Fungi / Q000187:drug effects / Q000302:isolation & purification* / Q000378:metabolism*; D009894:Opportunistic Infections / Q000382:microbiology; D011010:Pneumocystis / Q000187:drug effects / Q000302:isolation & purification* / Q000378:metabolism*; D011020:Pneumonia, Pneumocystis / Q000382:microbiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013045:Species Specificity
D000935:Antifungal Agents; D010129:4-Aminobenzoic Acid